MHC class II defi ciency or bare lymphocyte syndrome (BLS) is a severe combined immunodefi ciency disease. BLS is primarily characterized by an absence of MHC class II expression. Consequently, these patients manifest severely impaired humoral and cellular immune responses and impaired development of CD4+ T cells. The disease is caused by defects in MHC-specifi c regulatory factors and it is inherited in an autosomal recessive fashion.
the transcriptional start site, which consisted of a repeated 15 base pairs core element. Effectively, this insertion silenced the RFXAP promoter as defi ned in promoter-reporter assays and no RFXAP mRNA could be detected in this patients T cell lines. Together, we have identifi ed a novel type of gene silencing among BLS patients at the level of transcriptional control of regulatory factors, which are essential for MHC class II gene transcription.
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INDUCIBLE KNOCKDOWN OF HLA EXPRESSION
Constança Figueiredo, Axel Seltsam, Peter A. Horn, Rainer Blasczyk Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany HLA polymorphism is the most relevant barrier to the development of cell-based therapies for regenerative purposes. To overcome this limitation, we used RNA interference (RNAi) to specifi cally knock down HLA class I transcripts.
Regions susceptible to the action of small interfering RNAs (siRNAs) were identifi ed in HLA-A heavy chain and B2-microglobulin (B2m) transcripts to achieve a gene or class I specifi c HLA silencing, respectively. Lentiviral vectors were designed to express short hairpin RNA sequences (shRNA) targeting HLA-A heavy chain or B2m constitutively or controlled by a doxycycline-inducible promoter system. The level of HLA suppression in HeLa cells and B-LCLs was detected by fl ow cytometry, real-time RT-PCR and Western Blot. Complement-dependent cytotoxicity assays were performed to evaluate the protective effect of HLA suppression against immune response.
Hela cells stably transduced with lentivirus expressing shRNA showed a reduction of 85% in HLA-A and 50% in β2m. The transduction of inducible RNAi cassettes containing the sequences for shRNAs targeting B2m suppressed HLA class I expression up to 50% in HeLa or 60% in B-LCLs in a fully reversible manner. In a complement-mediated cytotoxicity assay it was demonstrated that HLA knockdown was very effective in preventing antibody-mediated cell lysis.
In conclusion, we demonstrated the feasibility of controlling HLA expression by genetically modifying cell-based therapeutics to overcome the limitations of immunological rejection, bringing cellular therapies closer to reality. In contrast to the other cell surface expressed CD1 molecules, CD1e displays an unusual cellular distribution which in dendritic cells (DCs) depends on their stage of maturation. In immature DCs (I DCs), CD1e is mainly localized in the Golgi compartment, is not expressed on the plasma membrane and reaches late endosomes where it is cleaved at the junction between the transmembrane and the luminal domains. Conversely, in mature DCs (mDCs), CD1e is only found in late endosomes/lysosomes. We here studied the biosynthesis and cellular pathway of CD1e in immature and maturing DCs. CD1e synthesis was found to progressively declined after the induction of DC maturation, while the endosomal cleavage of CD1e still occurred. Confocal microscopy demonstrated that CD1e transit from the Golgi apparatus to late endosomal compartments through sorting endosomes, without passing through the plasma membrane in either immature or maturing cells. Upon DC maturation, CD1e disappeared from the Golgi, and transiently localized in HLA-DR+ vesicles, while the number of CD1e+/CD1b+ endosomes increased for at least 20 hours. The accumulation of CD1e in lysosomes of mDCs, as compared to iDCs, was confi rmed by electron microscopy. In iDCs, CD1e could be detected in the endoplasmic reticulum, in the Golgi, in sorting endosomes, in late endosomal multivesicular bodies and occasionally in the multilaminar MHC class II compartments (MIICs). In contrast, in mDCs CD1e was now easily detected in the so-called mature dendritic cell lysosomes (MDLs). Thus, we confi rmed by electron microscopy that, in marked contrast with the reported rather unaffected localization of other CD1 molecules, CD1e is absent from the cell surface and massively redistributed upon DC maturation to the MDLs, suggesting a role of CD1e in the presentation of antigen by other CD1 antigen presenting molecules.
SERIAL PERIPHERAL BLOOD IL-18 AND PERFORIN GENE EXPRESSION MEASUREMENTS FOR PREDICTION OF ACUTE KIDNEY GRAFT REJECTION
C Süsal1, T Simon1, J Schmidt2, S Pelzl1, and G Opelz1 1Department of Transplantation Immunology, Institute of Immunology and 2Surgical Clinic, University of Heidelberg, 69120 Heidelberg, Germany We and others have previously shown that expression of cytotoxic T lymphocyte (CTL) effector gene perforin in the peripheral blood is a strong predictor of acute rejection in the early post-transplant period. In the present study we investigated whether IL-18, an immunostimulatory gene which upregulates perforin-dependent cytotoxicity and promotes tissue damage through other non-CTL mechanisms, alone or in combination with perforin gene expression, may serve as a better predictor of renal allograft rejection in the fi rst weeks following transplantation.
Peripheral blood was collected twice weekly and gene expression was measured using real-time PCR.
Recipients with acute rejection (n=17) had higher levels of perforin and IL-18 transcript on days 5-7, 8-10, and 11-13, as compared to patients without rejection (n=37, P<0.01 in all cases). Rejection diagnosis using gene expression criteria was possible 1 to 32 days before traditional diagnosis (median 11 days). High specifi city was associated with IL-18 expression (72-93%) and high sensitivity with perforin expression (63-90%). Positive predictive value was optimized (78-100%) by using combined upregulation in both genes as a diagnostic criterion (double-positive). Using high expression in "either or both" genes as a diagnostic criterion yielded high sensitivity (82-91%) and high negative predictive value (91-96%).
Our data indicate that combined perforin and IL-18 gene expression measurements are useful tools for the recognition of graft rejection in its earliest stages. Serial measurements could be implemented as a monitoring system to identify patients at higher risk of rejection, making them candidates for biopsy or prophylactic increases in immunosuppression. Because of their central role in initiating immune responses, dendritic cells (DC) are considered to be a pivotal target for the induction of transplantation tolerance. We studied 2 differentially modulated DC for their capacity to induce regulatory T cells.
DIFFERENTIALLY MODULATED DENDRITIC CELLS INDUCE DIFFERENT TYPES OF REGULATORY T CELLS
Both dexamethason (DEX) treated DC triggered through LPS for 48 hours (DEX-LPS48hr-DC) and DEX treated DC triggered through LPS for 6 hours (DEX-LPS6hr-DC) acquired low levels of costimulatory, adhesion, and MHC class II molecules when compared with mature DC. Furthermore, DEX-LPS6hr-DC produced signifi cant amounts of IL-10 whereas DEX-LPS48hr-DC did not produce detectable levels of IL-10 (and IL-12). In contrast, the number of IL-10 producing cells was signifi cantly increased when PBL were stimulated with DEX-LPS48hr-DC compared with DEX-LPS6hr-DC.
Both the IL-10 producing cells, induced by DEX-LPS48hr-DC, and the non-IL-10 producing cells, induced by DEX-LPS6hr-DC, exhibited downregulating potential of the alloimmune reponse of CD4 + cells in coculture experiments. Furthermore, both types of cell populations inhibit the alloresponse in a cell-contact independent fashion via a soluble factor. The IL-10 producing cells act most certainly by IL-10 and the non-IL-10 producing cells act probably by TGF-β.
These data show that different protocols of modulated DC induce different populations of regulatory T cells. In addition, the present data suggest that modulated DC may become an attractive tool for the induction of transplantation tolerance in the clinical setting.
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COMPREHENSIVE PEPTIDE BINDING PREDICTION BY DEVELOPING A MODULAR CONCEPT FOR HLA PEPTIDE BINDING POCKETS
David DeLuca, Barbara Khattab, Rainer Blasczyk Department of Transfusion Medicine, Hannover Medical School, Hannover, Germany A variety of algorithms have been successful in predicting HLA-peptide binding for HLA variants, for which plentiful experimental binding data exists. While predicting binding for only the most common HLA variants may provide suffi cient population coverage for vaccine design, successful prediction for as many HLA variants as possible is necessary to understand the immune response in transplantation. The high cost of peptide sequencing limits the acquisition of binding data. A prediction algorithm, which applies the binding information from well studied HLA variants to HLA variants, for which no peptide data exist, is necessary. To this end, we have developed a modular concept of HLA-peptide binding prediction. Highly accurate predictions were made for the following alleles without using experimental peptide binding data specifi c to those alleles: A*0201, A*0206, A*0214, B*2705, B*3501, B*5102, B*5301. Using the MHCBN peptide database, and a minimum cutoff of 15 peptides, the modular concept increases the number of predictable alleles from 15 (4.5%) to 75 (22.3%) of HLA-A and 12 (2.0%) to 36 (5.9%) of HLA-B proteins. Under the modular concept, binding data of certain HLA molecules can make prediction possible for numerous additional HLA alleles. In this regard, the HLA molecules A*7401, 3201, 6813; B*1803, 4103, 3908 have been identifi ed to be the most informative. Achieving peptide binding prediction for all HLA molecules will provide a major basis for individualizing the clinical application of the minor histocompatibility concept and the management of Graft versus Leukemia reactions.
7
UP REGULATION OF HLA CLASS I UNDER G INTERFERON (IFN) DEPENDS ON CD99
Sylvie Coito, Ophelie Meynet, Aurore Bremond, Alain Bernard, Ghislaine Bernard INSERM U 576, Hopital de l'Archet I, route de Saint Antoine de Ginestiere, 06202 Nice, France CD99 is a 32kd transmembrane molecule which belongs to a new family of proteins .We describe here that CD99 powerfully regulates the level of HLA class I. The expression of HLA class I is tightly linked to the surface of variants from the same cell line ; CD99 negative cells (CD99 neg) display a level of class I reduced by half as compared to wild type (wt) cells. After CD99 cDNA transfection, HLA class I expression was fully recovered. Strikingly, gIFN lead to an up-regulation of class I expression on CD99 neg cells two fold less important compared to the increase of class I expression on CD99 retransfected cells. Of note, gIFN did not affect CD99 expression. We have observed, using confocal microscopy that, contrary to CD99 positive cells, HLA class I molecules were stored in the cytoplasmic vesicules and less exported to the cell surface in CD99 neg cells. Yet, we observed no modifi cation of the transcription level of the antigen processing machinery genes.
Our observations might be relevant to tumor and virus escape since loss or down regulation of HLA class I molecules is an important feature which keep tumors and virus infected cells below the cytotoxic T-cell detection levels.
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RELEVANCE OF KIR GENE POLYMORPHISM IN UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATIONS K Gagne1, M Busson2, ML Appert2, L Absi3, D Alcalay4, JD Bignon1, M Bois4, A Dormoy5, V Dubois6, L Gebuhrer6, V Lepage2,7, P Loiseau2,7, D Masson8, A Moine8, P Perrier9, D Reviron10, C Raffoux11 on behalf of ARS2000 FRM group (D Charron2,7) 1EFS Nantes, 2U396, Paris, 3EFS Saint-Etienne, 4EFS Poitiers, 5EFS Strasbourg, 6EFS Lyon, 7Saint-Louis, Paris, 8EFS Grenoble, 9EFS Nancy, 10EFS Marseille, 11FGM, Paris, FRANCE Killer immunoglobulin-like receptors (KIR) are expressed on Natural Killer (NK) cells and a subpopulation of CD8 T lymphocytes. Failure to recognize the appropriate KIR ligand (HLA molecules) on a HLA class I mismatched cell may trigger NK cell alloreactivity. Because KIR and HLA genes are located on different chromosomes, matching for HLA genes mostly does not result in matched KIR genes in HLA identical hematopoietic stem cell transplantation (HSCT). In this context, we have retrospectively analysed KIR gene disparities in 174 donor-recipient pairs from HLA-matched unrelated HSCT performed for lymphoid and myeloid malignant diseases in 9 French centers from 1993 to 2003. Genotyping of inhibitory (2DL1, 2DL2, 2DL3, 2DL4, 2DL5, 3DL1, 3DL2, 3DL3) and activating (2DS1, 2DS2, 2DS3, 2DS4, 2DS5, 3DS1) KIR genes was performed using a PCR-SSP method. In an univariate analysis, we found that donor-recipient mismatching for 2DS1 or 2DS5 (namely activating KIR genes) was associated with the higher incidence of acute GvHD II-IV (p=0.05 and p=0.03 respectively). In the same way, cumulative mismatches for activating KIR genes (2DS1, 2DS2, 2DS3, 2DS4, 2DS5 and 3DS1) statistically increased aGvHD risk (p=0.02, grades 0-I vs II-IV). Moreover, analysis of KIR gene disparities on overall survival showed that donor-recipient pairs mismatched for the inhibitory KIR3DL1 gene were associated with decreased survival (p=0.02). Overall, our results suggest a detrimental effect of a few KIR gene incompatibilities (mainly activating KIR genes) that should be avoided in HLA identical unrelated HSCT.
